Bovine lactoferrin hydrolysate inhibited staphylococcal biofilm formation at 2.5 mg/mL — far below the concentration needed to kill the bacteria directly — suggesting biofilm-specific applications for skincare.
2.5 mg/mL biofilm inhibitionLactoferrin hydrolysate prevented staph biofilm formation at 4-8x lower concentration than needed to kill bacteria directly
What the researchers found
Bovine lactoferrin hydrolysate achieved a minimal biofilm inhibitory concentration (MIBC) of 2.5 mg/mL against most staphylococcal strains — 4-8x lower than the minimal inhibitory concentration for direct killing. Purified peptides LFcinB and LFampin showed even lower MIBCs.
Why it matters
Biofilm-forming staphylococci on skin cause body odor, infections in immunocompromised patients, and catheter/implant complications. Lactoferrin peptides could offer a natural, cosmetic-grade biofilm control strategy.
The numbers in context
HLF MIC 10->20 mg/mL; MIBC 2.5 mg/mL; individual peptides effective at lower concentrations; high eradication by dipping/spraying
How the study worked
In vitro testing of bovine lactoferrin hydrolysate and purified peptides (LFcinB, LFampin) against coagulase-negative and positive staphylococci. Measured MIC, MIBC, and biofilm eradication on glass surfaces via dipping and spraying applications.
Who was studied
Coagulase-negative and positive staphylococci (skin-related strains)
What this study cannot tell us
In vitro study on glass surfaces — skin conditions differ significantly. No human skin testing. The gap between MIC and MIBC may limit effectiveness against established infections. Stability in cosmetic formulations not tested.
How to read the evidence
Preliminary — in vitro testing on glass surfaces; no skin model or human testing performed.
When this study was published
Published in 2020; lactoferrin-based skincare ingredients continue to gain commercial interest.
The bigger picture
This research bridges antimicrobial peptide science and cosmetics/personal care, showing that biofilm disruption — rather than bacterial killing — may be the more practical target for skin health products.
Questions still open
- Do lactoferrin peptides maintain anti-biofilm activity when formulated into skincare products?
- How do these peptides affect beneficial skin microbiome bacteria?
- Would topical lactoferrin peptides reduce body odor or skin infections in clinical testing?
Common questions
Why target biofilms instead of just killing bacteria?
Could lactoferrin peptides replace antibiotics for skin infections?
Read the original research
Lactoferrin-Derived Peptides as a Control Strategy against Skinborne Staphylococcal Biofilms.
Biomedicines, 8(9)
Citation
Quintieri, Laura; Caputo, Leonardo; Monaci, Linda; Cavalluzzi, Maria Maddalena; Denora, Nunzio. (2020). Lactoferrin-Derived Peptides as a Control Strategy against Skinborne Staphylococcal Biofilms.. Biomedicines, 8(9). https://doi.org/10.3390/biomedicines8090323